9. January 2015

FDA Approves Roche's Blood Screening Assay for Simultaneous Detection and Identification of Three Major Viral Targets

Roche announced today that the FDA has approved the cobas® TaqScreen MPX Test, v2.0 for use in the detection and identification of HIV, HCV, and HBV in donations of human whole blood and blood components including source plasma.

>more

Learn about testing for Influenza
 
What's New

30. March 2016

Roche to initiate testing for Zika virus at U.S. Blood Centres under FDA Investigational New Drug Application protocol

New cobas® Zika test will screen blood samples on the cobas® 6800/8800 Systems.

>more

10. March 2016

Roche receives approval in Japan for the cobas® EGFR Mutation Test v2

New test includes expanded mutation coverage to detect EGFR mutations in non-small cell lung cancer patients.

>more

22. December 2015

New Roche HBV Test expands cobas® 4800 System menu

Complete virology portfolio strengthens high medical value capabilities.

>more

21. December 2015

Roche receives FDA approval for HIV-1 viral load test on the cobas® 6800/8800 Systems

HIV-1 test expands menu for highly automated molecular platforms that offer fastest time to results.

>more

 Diagnostic and Blood Screening Tests

 

Roche Molecular Diagnostics (RMD) offers a uniquely broad range of diagnostic and blood screening assays based on the company's Nobel prize-winning PCR technologies.

 

RMD's tests and automated platforms are focused in the areas of virology, blood screening, HPV, genomics and oncology, microbiology and sexually transmitted infections. > more

 Contact

Contact your local sales representative for detailed information, questions and ordering.

 

 

 Browse Our Products

 Related Links